tion are shown in Tables 2 and 3 , respectively. At the time of GKS, 19 patients (26%) had useful hearing (GardnerRobertson Class I or II) and 59 (78%) had normal facial function.
Radiosurgical Procedures
Gamma knife surgery was performed with the aid of the Leksell stereotactic frame (model G; Elekta Instruments, Atlanta, GA). The frame was applied after mild sedation and local anesthesia had been administered, and thereafter all patients underwent MR imaging studies. Axial and coronal T 1 -weighted images with contrast enhancement were used in dose planning, as was a dose-planning system (KULA system; Elekta Instruments). The maximal and tumor margin doses varied from 16 to 36 Gy (mean maximal dose 28.4 Gy) and from 10 to 18 Gy (mean tumor margin dose 14.6 Gy), respectively. The isodose line for the tumor margin varied from 40 to 80% (mean isodose line 52%). Tumor volume varied from 0.2 to 36.7 cm 3 (mean volume 6.3 cm ). Radiosurgical doses to the tumor margin were higher than those presently in use (12) (13) .
Follow-Up Analysis
Clinical follow-up data were obtained from either the patient or his or her referring doctor if they lived a great distance from our institution. When necessary, patients were contacted by telephone to update their outcome statuses for the purposes of this study. Hearing was evaluated using serial audiometry. Neuroimaging studies were requested at 3-month intervals for the 1st year after GKS, at 6-month intervals for the next 2 years, and annually thereafter. Tumor enlargement or regression was defined as a change of Ϯ 2 mm in one direction, which was measured using calipers.
Statistical Analysis
Progression-free survival was calculated using the product limit method of Kaplan and Meier. When figuring PFS, treatment failure was defined as tumor progression or radiation-induced peritumoral edema requiring resection. To analyze factors correlated with PFS we assessed the following: patient age (Ͻ 65 years compared with Ն 65 years), patient sex (male compared with female), tumor type (type A compared with type B), maximal radiation dose (Ͻ 28 Gy compared with Ն 28 Gy), tumor margin dose (Ͻ 15 Gy compared with Ն 15 Gy), number of isocenters (Ͻ 5 compared with Ն 5), prior treatment (no compared with yes), and tumor volume (Ͻ 10 cm 3 compared with Ն 10 cm 3 ). Factors affecting PFS were assessed using the logrank test and the Cox proportional hazards model. A final multivariate analysis was performed using a stepwise backward elimination.
Results
In this study, the median follow-up period was 135 months. In December 2003, 68 patients were alive and five were dead. One patient died of complications related to radiation-induced edema 19 months after GKS.
Tumor Control
In 71 of 73 patients, follow-up MR images had been ob-
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Gamma knife surgery for vestibular schwannomas tained. At the last follow up, 48 patients (68%) had partial tumor remission, 14 (20%) had tumors that remained stable, and nine (13%) experienced treatment failure-tumor enlargement (7%) in five patients and radiation-induced edema (6%) requiring surgical resection in three patients and causing death in one patient. In the nine patients with treatment failure, the time to therapeutic failure following GKS varied from 3 to 27 months. Actuarial 10-year PFS was 87% ( (Table 4) . Of 31 patients who had undergone follow up at our institution, additional tumor shrinkage occurred in 26 (84%), according to the last MR image obtained immediately after GKS compared with that obtained 5 years after GKS (Fig.  3 ). Although several patients showed slight tumor expansion at 5 years after GKS, the tumor size had decreased 10 years after GKS with no additional treatment (Fig. 4) . No patient with tumor control at the 5-year follow up experienced tumor recurrence thereafter.
11

Salvage Treatment
Of 73 patients, 11 (15%) underwent additional treatment following GKS. Seven patients underwent craniotomythree despite an unchanged tumor volume or only a slight tumor expansion 19, 28, and 56 months after GKS. Four patients underwent a second GKS session 24, 27, 32, and 38 months after the first procedure. Among these four, three patients demonstrated tumor shrinkage and one patient underwent a third GKS procedure 114 months and a craniotomy 124 months after the first GKS. Nine patients (12%) had hydrocephalus requiring placement of a ventriculoperitoneal shunt (mean tumor volume 12.7 cm 
Hearing Preservation
Both pre-and postradiosurgical hearing function based on the Gardner-Robertson classification are featured in Table 2. Audiometric evaluations were conducted in 69 patients. In four patients, a hearing test was not performed or could not be assessed due to early tumor resection. Nineteen patients (28%) had useful hearing before treatment. After GKS, hearing function was unchanged in 47 patients (68%) and had deteriorated in 22 (32%); no patient had improved hearing after GKS. Of the 19 patients with useful hearing before GKS, useful hearing was preserved in seven (37%).
Other Complications
Eight patients (11%) suffered persistent (five patients) or transient (three patients) facial palsy 6 to 15 months after GKS. Six patients (8%) developed facial numbness 6 to 13 months after GKS. This numbness was transient in two pa- tients. One patient (1%) had facial spasm. Malignant transformation occurred in no one.
Discussion
Tumor Control
In this study, the tumor control rate (partial remission or stable) was 87% 10 years after GKS. Compared with the results in other reports, this rate seems a little low for vestibular schwannomas treated using GKS. Note, however, that these lesions occurred in patients who were treated in the early days of GKS. Until 1996 we used the KULA system. Now we use GammaPlan software (Elekta Instruments) so that axial images can be reformatted into coronal and sagittal ones, thus helping to make more conformal plans. In five of nine patients whose tumor did not respond to treatment, the lesion volume was greater than 15 cm patient whose tumor volume was greater than 20 cm 3 developed radiation-induced edema and died 19 months after GKS (Fig. 5) . Analysis of these results indicates that tumors larger than 20 cm 3 were not suitable for GKS and that resection instead should have been performed. 18, 28, 32 Actuarial 10-year PFS in patients whose tumor volume was less than 10 cm 3 was 93%. Considering tumor diameter on MR images as an indication for GKS, treatment failure occurred in four of 50 patients with a mean tumor diameter of less than 2.5 cm, in none of 13 patients with a lesion diameter 2.5 to 3 cm, and in five of eight patients with a tumor diameter greater than 3 cm. In patients with a mean tumor diameter of more than 3 cm, the actuarial 10-year PFS was only 38% compared with 93% in patients with a lesion diameter less than 3 cm (p Ͻ 0.0001).
It is crucial to select patients who are suitable candidates for GKS. At present, we assert that GKS is appropriate in treating vestibular schwannomas less than 3 cm in mean diameter or less than 15 cm 3 in volume. Larger tumors causing symptomatic compression of the brainstem should be surgically removed first, and then residual or recurrent tumor can be managed with GKS. Four patients underwent a second GKS session 24, 27, 32, and 38 months after the first procedure. Tumor remission occurred in three of these patients. One patient underwent a third GKS 114 months after the first procedure and a tumor resection at 125 months. In instances of initial treatment failure, the second GKS appeared to be as effective as the first procedure, although one should take care to avoid radiation injury. Fortunately, none of the patients in our study showed any new neurological deterioration after the second procedure.
In the early era of radiosurgery, three patients underwent craniotomy following GKS despite an unchanged or slight increase in tumor volume. It is not uncommon for a tumor temporarily to expand slightly with central necrosis before tumor shrinkage. 13, 14 Such a change usually occurs within 3 years after GKS, but should not be considered to indicate treatment failure. At 3 years after GKS, the patients' referring doctors decided to perform a resection because they did not understand the biological process that would likely lead to later tumor regression.
In this study, all treatment failures demonstrated on MR images occurred within 3 years after GKS and salvage treatments were performed within 5 years. Compared with MR images obtained 5 years after GKS, those obtained 10 years after demonstrated further tumor shrinkage in most cases (84%). Among patients with good tumor control by 5 years post-GKS, none demonstrated tumor recurrence after that. This result indicates that GKS remains effective more than 5 years after the procedure and that this time may be considered an end point of follow up. Noren 20 and colleagues 21 found that all vestibular schwannomas considered to be under control 5 years after GKS remained so after 20 years. Similarly, Kondziolka, et al., 13 reported long-term outcomes in 162 patients with 5 to 10 years of follow up. These investigators also determined that no treatment failure occurred in any patient after 3 years following GKS. Recently, Kondziolka, et al., 14 reported long-term results of more than 10 years for benign intracranial tumors in 285 patients, demonstrating that GKS provided high tumor control rates and low morbidity rates over the long term. They also showed that the 10-year actuarial tumor control rate for vestibular schwannomas was 97%. These reports were consistent with our findings.
Some researchers have been concerned about long-term outcomes in patients with benign tumors after treatment with GKS, because there has been no evidence that radiosurgery can prevent tumor growth over the long term. This concern has particularly been raised regarding younger patients. Although tumors can recur more than 10 years after GKS, they can also recur following resection. 1, 17, 27 Among patients who had undergone GKS in this study, hydrocephalus occurred in nine. The mean tumor volume in these patients was 12.7 cm 3 , and the tumor compressed the brainstem in six patients. Hydrocephalus is more likely to occur in patients with larger tumor volumes (p = 0.26, Fisher exact test), although the number of patients was too small to prove this trend conclusively.
Functional Results
Recently there has been a trend of patients having useful hearing when the vestibular schwannoma is diagnosed. In these cases, treatment options include microsurgery, radiosurgery, fractionated radiotherapy, or observation. 12, 15, 18, 28, 32, 33 The choice of treatment remains controversial. According to an analysis of conservative management, the majority of vestibular schwannomas grow slowly but eventually require intervention. As a result, one third of patients lose useful hearing and more than 70% lose their eligibility for tumor removal with hearing preservation. 33 Although microsurgery can often be used to remove the tumor completely, this procedure frequently resulted in hearing loss or facial palsy despite recent improvements in microsurgical techniques. 12, 26, 31 Moreover, severe morbidity or death was not completely eliminated. 27 Therefore, stereotactic radiosurgery has been established as a therapeutic alternative. According to data in recent publications, hearing is preserved at a rate of approximately 40 to 70% following reduced-dose radiosurgery. 3, 11, 24, 26 The variance in these rates depends heavily on patient selection. Iwai, et al., 11 reported that hearing was preserved in 56% of patients with preradiosurgically useful hearing who had been treated with a low dose of 8 to 12 Gy to the tumor margin. Nine percent of patients had improved hearing. Flickinger, et al., 3 reported that hearing was preserved in 74% of patients with useful hearing before surgery who received a mean dose of 13 Gy to the tumor margin. In this study of higher radiation doses, the hearing preservation rate in patients with previously useful hearing was 37% and no patient had improved hearing function. Persistent or transient facial palsy developed in 11% of patients. These results seem to be worse compared with those in other recent reports. This is not surprising, however, given that we used higher tumor margin doses of 14 to 17 Gy for small lesions in the early days of GKS, which emphasizes our learning curve in this setting. Of 19 patients who had useful hearing before GKS, hearing was preserved in seven and worsened in 12. Eleven of 12 patients with worsened hearing received a tumor margin dose of more than 14 Gy. On the other hand, six of seven patients with preserved hearing received a tumor margin dose of 13 Gy or less. A tumor margin dose of 13 Gy or less led to a significantly better rate of hearing preservation (p = 0.0017, Fisher exact test). Niranjan, et al., 19 reported useful hearing in 10 of 10 patients who had received a tumor margin dose of 14 Gy or less but in only one of five patients who had received more than 14 Gy. At present, we use a reduced tumor margin dose of 11 to 13 Gy regardless of hearing function. In addition, we use multiple isocenters to make a more conformal dose plan with thin-sliced MR images. With these refinements, we are able dramatically to reduce complications such as hearing deterioration, facial numbness, facial palsy, or radiation-induced edema. Currently, our rate of facial palsy is close to zero. With the introduction of the new gamma knife (model C) with its automatic positioning, which makes it easier to make a more conformal plan with an increased number of isocenters, further reductions in complication rates are expected. 8, 25 Nonetheless, it will be necessary to follow up patients treated using a reduced radiation dose to make sure of the efficacy at 10 years.
Conclusions
Gamma knife surgery remained effective for more than 10 years in the majority of patients harboring a vestibular schwannoma, indicating that radiosurgery can be an acceptable alternative to resection in selected patients. No patient had developed delayed malignant transformation during the time of this study. No patient with good tumor control after 5 years following GKS developed tumor recurrence or underwent further treatment. These results may indicate that an acceptable end point for follow up of a vestibular schwannoma treated using GKS is 5 years. Regardless, we will continue to follow up our patients as we learn more about even longer-term outcomes.
